Publications by authors named "Alessandra Ferro"

Claim this Profile
A
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials.
Francesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, Francesca Ambrosi, Alessandro Di Federico, Alessandra Ferro

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic assessment of resected stage III non-small cell lung cancer after neoadjuvant chemotherapy: identification of additional prognostic factors.
Francesca Lunardi, Alessandra Ferro, Luca Vedovelli, Federica Pezzuto, Sofia-Eleni Tzorakoleftheraki

Histopathology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RadiomiX for Radiomics Analysis: Automated Approaches to Overcome Challenges in Replicability.
Harel Kotler, Luca Bergamin, Fabio Aiolli, Elena Scagliori, Angela Grassi, Alessandra Ferro

Diagnostics (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257).
Giulia Pasello, Giulia Pigato, Daniela Scattolin, Stefania Lando, Sara Potente, Alessandra Ferro

J Exp Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer.
Alessandro Dal Maso, Federica Ferrarini, Giovanni Esposito, Sonia Anna Minuzzo, Anna Maria Puggia, Alessandra Ferro

Front Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
Daniele Marinelli, Antonio Nuccio, Alessandro Di Federico, Francesca Ambrosi, Pietro Bertoglio, Alessandra Ferro

J Thorac Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives.
Alessandra Ferro, Michele Bottosso, Maria Vittoria Dieci, Elena Scagliori, Federica Miglietta

Crit Rev Oncol Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Giulia Pasello, Martina Lorenzi, Daniela Scattolin, Alessandro Del Conte, Fabiana Cecere, Alessandra Ferro

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
Daniela Scattolin, Alessandro Dal Maso, Alessandra Ferro, Stefano Frega, Laura Bonanno

Cancer Treat Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis.
Giulia Pasello, Alberto Pavan, Mattia De Nuzzo, Stefano Frega, Alessandra Ferro

Front Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.
Alessandra Ferro, Gian Marco Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello

Crit Rev Oncol Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.
Laura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, Alberto Pavan, Loc Carlo Bao, Alessandra Ferro

Front Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
Martina Lorenzi, Maria Vittoria Resi, Laura Bonanno, Stefano Frega, Alessandro Dal Maso, Alessandra Ferro

Front Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
Laura Bonanno, Martina Lorenzi, Davide Massa, Mattia De Nuzzo, Valentina Angerilli, Alessandra Ferro

Oncologist· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments.
Alessandra Ferro, Matteo Sepulcri, Marco Schiavon, Elena Scagliori, Edoardo Mancin

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Alessandra Ferro

J Thorac Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
Alberto Pavan, Alessandra Ferro, Francesco Fortarezza, Marco Schiavon, Laura Evangelista

Oncologist· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte

Oncologist· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Cecere

Future Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in -Mutated Non-small Cell Lung Cancer: A Case Report.
Alessandra Ferro, Angela Filoni, Alberto Pavan, Giulia Pasello, Valentina Guarneri

Front Med (Lausanne)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, Alessandra Ferro, Elisabetta Zulato

Transl Lung Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Laura Bonanno, Alberto Pavan, Alessandra Ferro, Lorenzo Calvetti, Stefano Frega

Oncologist· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.
Stefano Frega, Alessandra Ferro, Laura Bonanno, Valentina Guarneri, PierFranco Conte

Int J Mol Sci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?" [Crit. Rev. Oncol. Hematol. 138 (June) (2019), 87-103].
Stefano Frega, Alessandro Dal Maso, Alessandra Ferro, Laura Bonanno, Pier Franco Conte

Crit Rev Oncol Hematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?
Stefano Frega, Alessandro Dal Maso, Alessandra Ferro, Laura Bonanno, PierFranco Conte

Crit Rev Oncol Hematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis